
    
      This research study is a PhaseI/II clinical trial investing a combination of targeted
      therapies as possible treatment for advanced solid cancers

      FDA has not yet approved Poly-ICLC as treatment for diseases in this study

      Pembrolizumab, Nivolumab, Atezolizumab, Cemiplimab and Durvalumab are now FDA approved for
      certain patients with multiple cancer types.

      The study is designed to evaluate the safety of intramuscular (IM) Polyinosinic-polycytidylic
      acid stabilized with polylysine and carboxymethylcellulose (Poly-ICLC, HiltonolÂ®) in
      combination with Anti-PD-1 or Anti-PD-L1 for treatment of study subjects with advanced solid
      cancers.
    
  